Fortunato Ciardiello

University of Campania "Luigi Vanvitelli"

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Teresa Troiani

University of Campania "Luigi Vanvitelli"

Stefania Napolitano

University of Campania "Luigi Vanvitelli"

Giulia Martini

University of Campania "Luigi Vanvitelli"

Davide Ciardiello

European Institute of Oncology

Erika Martinelli

University of Campania "Luigi Vanvitelli"

Vincenzo De Falco

University of Campania "Luigi Vanvitelli"

Josep Tabernero

Universitat de Vic - Universitat Central de Catalunya

Vincenzo Famiglietti

University of Campania "Luigi Vanvitelli"

Lucia Altucci

University of Campania "Luigi Vanvitelli"

Antonio Avallone

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Cooperative Institutions

University of Campania "Luigi Vanvitelli"

193

University of Naples Federico II

143

Istituti di Ricovero e Cura a Carattere Scientifico

124

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli

Centro de Investigación Biomédica en Red de Cáncer

The University of Texas MD Anderson Cancer Center

Federico II University Hospital

University of Turin

Fondazione IRCCS Istituto Nazionale dei Tumori

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Immunotherapy for head and neck cancer: Present and future

Critical Reviews in Oncology/Hematology (2022)

Morena Fasano Carminia Maria Della Corte Raimondo Di Liello Giuseppe Viscardi Francesca Sparano

Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC). Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for different disease settings and many others, alone or in combination, are currently under investigation. Otherwise, as in other cancer types, efficacy, and resistance mechanisms, are not clearly understood. Considering the heterogeneity of the benefit reported in clinical trials, cost-efficacy analysis and the development of an effective patient selection are encouraged. Different pathways involving innate immunity, regulatory T lymphocytes and microbiome are emerging as new potential biomarkers, supported by preclinical and translational data. In this review we report current evidence on immunotherapy in HNC with updates from the main 2021 oncology events as ASCO, AACR and ESMO meetings. We focus on clinical trials results of single agent and combination immunotherapy in different clinical scenario, from (neo)adjuvant to metastatic setting, describing also novel evidence about efficacy and resistance biomarkers.

Cancer Immunotherapy

10.1016/j.critrevonc.2022.103679

Cite

Citations (71)

ESMO Open (2016)

Josep Tabernero Malvika Vyas R. Giuliani Dirk Arnold Fátima Cardoso

Biosimilars present a necessary and timely opportunity for physicians, patients and healthcare systems. If suitably developed clinically, manufactured to the correct standards and used appropriately, they can positively impact on the financial sustainability of healthcare systems. A critical consideration regarding the introduction of biosimilars into the clinic centres on the required information concerning all the respective procedures. This position paper aims to describe the issues revolving around biosimilars that are relevant to the field of oncology, especially the prescribers. More specifically, we discuss aspects related to definition, forms of biosimilars, labelling, extrapolation, interchangeability, switching, automatic substitution, clinical standards on safety and efficacy, responsibilities among prescribers and pharmacists, potential impact on financial burden in healthcare and the current scenario and future prospects of biosimilars in Europe and the rest of the world.

Biosimilar

Position paper

Radiation oncology

10.1136/esmoopen-2016-000142

Cite

Citations (109)

Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data

Journal of Personalized Medicine (2022)

Emilia Sardo Stefania Napolitano Carminia Maria Della Corte Davide Ciardiello Antonio Raucci

Colorectal cancer (CRC) is one of the most frequent tumours and one of the major causes of morbidity and mortality globally. Its incidence has increased in recent years and could be linked to unhealthy dietary habits combined with environmental and hereditary factors, which can lead to genetic and epigenetic changes and induce tumour development. The model of CRC progression has always been based on a genomic, parametric, static and complex approach involving oncogenes and tumour suppressor genes. Recent advances in omics sciences have sought a paradigm shift to a multiparametric, immunological-stromal, and dynamic approach for a better understanding of carcinogenesis and tumour heterogeneity. In the present paper, we review the most important preclinical and clinical data and present recent discoveries in the field of transcriptomics, proteomics, metagenomics and radiomics in CRC disease.

Omics

10.3390/jpm12020128

Cite

Citations (11)

BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives

Cancer Treatment Reviews (2025)

Stefania Napolitano Davide Ciardiello Eleonora Cioli Erika Martinelli Teresa Troiani

10.1016/j.ctrv.2025.102905

Cite

Citations (0)

614P Effect of KRASG12 mutations on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial

Annals of Oncology (2023)

Josep Tabernero Gerald W. Prager Marwan Fakih Fortunato Ciardiello Eric Van Cutsem

Post-hoc analysis

Refractory (planetary science)

Subgroup analysis

10.1016/j.annonc.2023.09.1805

Cite

Citations (2)

Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial

Clinical Drug Investigation (2024)

Erika Martinelli Davide Ciardiello Giulia Martini Stefania Napolitano Sara Del Tufo

Pharmacotherapy

10.1007/s40261-024-01372-0

Cite

Citations (0)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis

Frontiers in Oncology (2022)

Anna Diana Francesca Carlino Giuseppe Buono Giuliano Antoniol Vincenzo Famiglietti

In luminal-like early breast cancer (BC), the lack of Progesterone Receptor (PR) expression generally correlates with more aggressive behavior but the clinical validity of low PR levels remains a debated issue.The main aim of this retrospective analysis was to assess the survival outcome (Breast cancer specific survival, BCSS) in a cohort of 687 luminal-like HER2 negative early BC patients treated at our Institutions from January 2000 to December 2018, using a sub-classification of tumors in subgroup 1 (PR high/Ki67 low), subgroup 2 (PR high/Ki67 high), subgroup 3 (PR low/Ki67 low), subgroup 4 (PR low/Ki67 high) according to PR and Ki67 values.At a median follow-up of 7 years, BCSS rates were 96.3%, 89%, 86.8% and 85% in the subgroup 1, 2, 3, 4 respectively. Overall, a statistically significant difference in BCSS rates was observed among the 4 subgroups (p=0.0036). On univariate analysis, post-menopause, older age (≥ 50 years), low PR and high Ki67 expression, poorly differentiated grade and size ≥ 2 cm as well as luminal B-like tumors (subgroups 2, 3, 4) were significantly associated with a worse BCSS. Multivariate analysis identified grade, size and subgroup classification of BC as independent prognostic markers of poorer outcome. In particular, subgroups 4, 3 and 2 displayed a significantly higher risk of BC-related death (HR=4.11; p=0.008; HR=3.43; p=0-007; HR=2.57; p=0.020, respectively) when compared to subgroup 1.Our results support the usefulness of PR and Ki67 levels as prognostic markers, corroborating their crucial role in the decision-making process of patients with luminal-like HER2 negative early BC. Clinical application of these parameters should be assessed prospectively.

Subgroup analysis

Univariate analysis

Progesterone receptor

10.3389/fonc.2022.813462

Cite

Citations (4)

Awareness and penetration of KRAS mutation testing in the treatment of patients with metastatic colorectal cancer.

Journal of Clinical Oncology (2010)

Fortunato Ciardiello Bruno Wohlschlegel T. Teague Domenica Mercadante

e14074 Background: The tumor mutation status of codons 12 and 13 of the KRAS gene is a predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC). KRAS testing may be used to direct epidermal growth factor receptor (EGFR)-targeting monoclonal antibody therapy to those pts most likely to benefit. This represents a significant change to standard diagnostic procedures and a major advance in relation to personalizing cancer care in this setting. Methods: A survey of physicians in 20 countries in Europe, Latin America and Asia was conducted to investigate the awareness, penetration and uptake of KRAS testing for pts with mCRC. Physicians answered questions on four or more of their recently treated pts. Data from 2009 (fieldwork Feb-May) were compared with similar information collected during 2008 (fieldwork Jan-Apr). Results: Globally in 2009, of 1,254 responding physicians, 1,083 (86%) reported an awareness of KRAS testing in this setting, most commonly in relation to cetuximab administration (53%). As to when such testing would be requested, this was on a routine basis in relation to mCRC diagnostics for 23% of responders, and prior to choice of first-, second- or third-line therapy, respectively for 43%, 30% and 21% of physicians, with 20% considering testing only if EGFR therapy was planned. Tumor KRAS mutational status was reportedly evaluated in 1,895 of 4,517 pts (42%), with 59% of tumors being assessed as wild-type. This contrasts with the 117/4,599 pts (2.5%) reported as tested in the 2008 survey, demonstrating the rapid adoption and uptake of KRAS testing after the ASCO 2008 publication of KRAS-related clinical data for the EGFR monoclonal antibody cetuximab. Globally, of those whose tumors were KRAS wild-type, 44% subsequently received cetuximab, 8% received bevacizumab and 2% received panitumumab, compared respectively with 3%, 2% and 0% in the 2008 survey. Conclusions: Most physicians are aware of the major significance of KRAS mutation testing in relation to personalizing anticancer therapy for pts with mCRC. KRAS testing is widely recognized as part of the routine diagnostic procedure for this disease, and is mainly performed before the choice of first-line treatment is made. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck Serono Merck Serono, Roche AstraZeneca, Merck Serono

10.1200/jco.2010.28.15_suppl.e14074

Cite

Citations (1)

Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis

International Journal of Molecular Sciences (2020)

Luca Pompella Giuseppe Tirino Annalisa Pappalardo Marianna Caterino Anna Ventriglia

Pancreatic cancer represents one of the most lethal disease worldwide but still orphan of a molecularly driven therapeutic approach, although many genomic and transcriptomic classifications have been proposed over the years. Clinical heterogeneity is a hallmark of this disease, as different patients show different responses to the same therapeutic regimens. However, genomic analyses revealed quite a homogeneous disease picture, with very common mutations in four genes only (KRAS, TP53, CDKN2A, and SMAD4) and a long tail of other mutated genes, with doubtful pathogenic meaning. Even bulk transcriptomic classifications could not resolve this great heterogeneity, as many informations related to small cell populations within cancer tissue could be lost. At the same time, single cell analysis has emerged as a powerful tool to dissect intratumoral heterogeneity like never before, with possibility of generating a new disease taxonomy at unprecedented molecular resolution. In this review, we summarize the most relevant genomic, bulk and single-cell transcriptomic classifications of pancreatic cancer, and try to understand how novel technologies, like single cell analysis, could lead to novel therapeutic strategies for this highly lethal disease.

10.3390/ijms21082814

Cite

Citations (28)

Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer

Critical Reviews in Oncology/Hematology (2022)

Maria Grazia Rodriquenz Davide Ciardiello Tiziana Pia Latiano Brigida Anna Maiorano Erika Martinelli

Targeted Therapy

10.1016/j.critrevonc.2022.103657

Cite

Citations (8)